Drug access opens for patients battling dangerous low platelet levels
NCT ID NCT04837703
Summary
This program provides access to the medication eltrombopag for patients with medically significant thrombocytopenia (low platelet count). Eligible patients include those with chronic immune thrombocytopenia (ITP), severe aplastic anemia, or hepatitis C who need interferon therapy and have no satisfactory alternative treatments. The program allows doctors to prescribe this medication following specific treatment guidelines for patients who meet the eligibility criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.